NCT07722767尚未招募1 期
A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 90
- 试验地点
- 3
- 主要终点
- Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax
研究概览
简要总结
A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥ 18 years of age with newly diagnosed, previously untreated AML (including MDS/AML)
- •Patients are not candidates for intensive induction chemotherapy because they are either unfit or otherwise clinically unsuitable for anthracycline/ cytarabine-based induction therapy
- •White blood cell (WBC) count at the time of C1D1 ≤ 20,000/μL
- •Patients must have previously untreated AML; hydroxyurea for cytoreduction is permitted up to C1D
- •Prior therapy for MDS is allowed except for hypomethylating agents and venetoclax.
- •Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 2
- •The patient's laboratory values meet the following criteria:
- •Creatinine clearance (CrCl) ≥ 45 mL/min;
- •Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN
排除标准
- •Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvement with AML to enter the study).
- •Diagnosis of acute promyelocytic leukemia or PML:RARA-positive AML.
- •Chronic myeloid leukemia in blast phase or AML with BCR:ABL
- •Mixed phenotype acute leukemia or acute leukemia of ambiguous lineage.
- •Active CNS involvement by AML.
- •Signs of leukostasis requiring urgent therapy.
- •Prior organ allograft, or prior allogeneic hematopoietic stem cell transplant within the last 12 months, or with active graph-versus-host disease.
- •Treatment with systemic glucocorticoid therapy or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-
- •Patients with concomitant second malignancies requiring active treatment in the past 12 months, or if additional therapy is required or anticipated during study participation.
- •Patients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or immunosuppressive medications
- •Active uncontrolled infection until infection is treated and brought under control.
- •Has a history of, or a positive test for human immunodeficiency virus (HIV) 1/2 or primary immunodeficiency disease such as HIV.
- •Known history of hepatitis B, hepatitis C (HCV) infection, or acute hepatitis A.
- •Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- •Patients who have received an investigational agent (for any indication) within 5 half-lives of the agent and until toxicity from this has resolved to Grade 1 or less
- •History of the following events in conjunction with prior treatment with immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis, myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's Law.
- •Live virus vaccines within 28 days of the first dose of CLN-049, during treatment, and until the end of last dose of CLN-
- •QT interval corrected for heart rate using Fridericia's formula (QTcF) of ≥ 480 milliseconds.
- •Patient has a history of drug-related anaphylactic reactions to any components of CLN-049, or a history of Grade 4 anaphylactic reaction to any bispecific molecule or monoclonal antibody therapy.
- •Known history of prior human anti-human antibody response.
结局指标
主要结局
Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax
时间窗: 48 weeks
Safety assessments include: body measurements, vital signs, physical exam, EGOG (measure of patient function in terms of self-care, daily activity, and physical ability) performance status, lab assessments, ECGs, and ECHO/MUGA (tests to evaluate heart function)
Determine recommended dose/schedule of CLN-049 in combination with azacitidine and venetoclax
时间窗: 48 weeks
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
招募中
1 期
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AMLMyelodysplastic SyndromeNCT07347418University of Colorado, Denver23
进行中（未招募）
1 期
A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent ThrombosisNCT07632976Shanghai Lanyi Therapeutics Co., Ltd.12
招募中
1 期
A Phase I clinical trial evaluating the Safety, Tolerability, and Efficacy of Oral AUR112 in Patients with Advanced CancerCTRI/2025/01/078964Aurigene Oncology Limited (Subsidiary of Dr Reddys Laboratories Limited )40
尚未招募
1 期
CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant TumorsNCT07657585Cancer Institute and Hospital, Chinese Academy of Medical Sciences91
招募中
1 期
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 MutationSolid Tumors (Phase 1)NCT07561554Haisco Pharmaceutical Group Co., Ltd.159